Q3 Earnings Forecast for CG Oncology Issued By HC Wainwright

Key Points

• HC Wainwright has raised its Q3 2025 earnings per share estimate for CG Oncology to ($0.55), up from ($0.58), maintaining a "Buy" rating with a target price of $75.00.
• The company's stock recently opened at $26.49, with a fifty-two week range between $14.80 and $40.47, and a market capitalization of $2.02 billion.
• Institutional investors have significantly increased their holdings in CG Oncology, with notable increases from the likes of CWM LLC and GAMMA Investing LLC, reflecting growing confidence in the company's future.

CG Oncology, Inc. (NASDAQ:CGON - Free Report) - Analysts at HC Wainwright increased their Q3 2025 earnings per share estimates for shares of CG Oncology in a report released on Monday, August 11th. HC Wainwright analyst A. Maldonado now anticipates that the company will earn ($0.55) per share for the quarter, up from their previous estimate of ($0.58). HC Wainwright currently has a "Buy" rating and a $75.00 price target on the stock. The consensus estimate for CG Oncology's current full-year earnings is ($1.31) per share. HC Wainwright also issued estimates for CG Oncology's Q4 2025 earnings at ($0.58) EPS, FY2025 earnings at ($2.13) EPS, FY2026 earnings at ($2.29) EPS, FY2027 earnings at ($1.77) EPS, FY2028 earnings at $0.08 EPS and FY2029 earnings at $1.85 EPS.

CG Oncology (NASDAQ:CGON - Get Free Report) last issued its earnings results on Friday, August 8th. The company reported ($0.54) earnings per share for the quarter, missing the consensus estimate of ($0.49) by ($0.05). CG Oncology had a negative return on equity of 19.37% and a negative net margin of 15,945.17%.

Several other research analysts have also recently issued reports on the company. Royal Bank Of Canada decreased their price target on CG Oncology from $68.00 to $53.00 and set an "outperform" rating for the company in a research note on Wednesday, July 16th. The Goldman Sachs Group upgraded CG Oncology to a "strong-buy" rating and set a $40.00 price target for the company in a research report on Thursday, July 10th. Morgan Stanley raised their price objective on CG Oncology from $52.00 to $56.00 and gave the stock an "overweight" rating in a research report on Tuesday, June 17th. Wall Street Zen lowered CG Oncology from a "hold" rating to a "sell" rating in a research report on Saturday, August 9th. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating and set a $75.00 price target on shares of CG Oncology in a research note on Monday, April 28th. One analyst has rated the stock with a sell rating, one has given a hold rating, nine have issued a buy rating and two have assigned a strong buy rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $55.30.

CG Oncology Stock Down 1.0%

NASDAQ CGON traded down $0.26 during trading hours on Thursday, hitting $25.70. The company had a trading volume of 588,838 shares, compared to its average volume of 929,940. CG Oncology has a fifty-two week low of $14.80 and a fifty-two week high of $40.47. The firm has a market cap of $1.96 billion, a P/E ratio of -14.52 and a beta of 0.87. The business has a fifty day simple moving average of $26.16 and a 200-day simple moving average of $25.47.

Institutional Trading of CG Oncology

Several institutional investors have recently modified their holdings of CGON. JPMorgan Chase & Co. grew its holdings in shares of CG Oncology by 443.5% during the fourth quarter. JPMorgan Chase & Co. now owns 168,866 shares of the company's stock worth $4,843,000 after purchasing an additional 137,795 shares during the last quarter. Geode Capital Management LLC raised its position in shares of CG Oncology by 7.2% during the fourth quarter. Geode Capital Management LLC now owns 1,156,670 shares of the company's stock worth $33,181,000 after purchasing an additional 78,143 shares during the period. Wells Fargo & Company MN grew its holdings in shares of CG Oncology by 45.3% during the fourth quarter. Wells Fargo & Company MN now owns 28,234 shares of the company's stock worth $810,000 after buying an additional 8,803 shares in the last quarter. Federated Hermes Inc. bought a new position in CG Oncology in the fourth quarter valued at approximately $172,000. Finally, Invesco Ltd. grew its stake in CG Oncology by 75.7% in the fourth quarter. Invesco Ltd. now owns 27,069 shares of the company's stock valued at $776,000 after purchasing an additional 11,662 shares in the last quarter. Institutional investors and hedge funds own 26.56% of the company's stock.

Insider Buying and Selling

In other CG Oncology news, Director Leonard E. Post sold 2,000 shares of CG Oncology stock in a transaction that occurred on Thursday, July 17th. The stock was sold at an average price of $28.00, for a total value of $56,000.00. The sale was disclosed in a filing with the SEC, which is available through this link. 7.40% of the stock is currently owned by corporate insiders.

About CG Oncology

CG Oncology, Inc, an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients.